Paper Details

  1. Home
  2. Paper Details

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.

Author: FriedmanAlan, FuldeoreMahesh, GanguliArijit, MeerweinSebastian, PanganAileen, PopeJanet, SchiffMichael, SongYan, StrandVibeke, TundiaNamita

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared upadacitinib with placebo in patients with rheumatoid arthritis who had inadequate responses to biologic disease-modifying antirheumatic drugs. Upadacitinib showed clinically meaningful improvements in patient-reported outcomes.
Paper Details　
Original Abstract of the Article :
Patient-reported outcomes (PROs) are important when evaluating treatment benefits in rheumatoid arthritis (RA). We compared upadacitinib, an oral, selective JAK-1 inhibitor, with placebo to assess clinically meaningful improvements in PROs in patients with RA who have had inadequate responses to bio...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889334/

データ提供：米国国立医学図書館（NLM）

Upadacitinib: A new oasis in the desert of rheumatoid arthritis treatment

This Phase 3 clinical trial explores the effects of upadacitinib, a novel oral medication targeting a specific protein involved in inflammation, for treating rheumatoid arthritis. The study examines the impact of upadacitinib on patient-reported outcomes, providing insights into the quality of life improvements experienced by patients.

Addressing a challenging landscape: Rheumatoid arthritis and its effects

Rheumatoid arthritis is a chronic inflammatory disease that affects millions of people worldwide. Imagine a desert ravaged by fierce sandstorms, leaving behind a landscape of pain and discomfort. This study investigates the potential of upadacitinib to provide relief and improve the quality of life for those living with rheumatoid arthritis, offering a potential oasis in this difficult terrain.

A promising alternative: A new route to managing rheumatoid arthritis

The study indicates that upadacitinib demonstrates significant improvement in patient-reported outcomes compared to placebo. This suggests that upadacitinib may offer a new and effective route for managing rheumatoid arthritis, like finding a smoother and more refreshing path through the desert of chronic inflammation. The study's findings offer hope for a more comfortable and manageable journey for patients with rheumatoid arthritis.

Dr.Camel's Conclusion

This study is a beacon of hope for patients with rheumatoid arthritis, like a shimmering oasis in a vast desert. Upadacitinib presents a promising new approach to managing this debilitating disease, offering the potential for improved quality of life and a more comfortable journey. As I, Dr. Camel, have learned from my travels, perseverance and innovation are key to overcoming the challenges of chronic illness.

Date :
  1. Date Completed 2020-09-09
  2. Date Revised 2023-10-20
Further Info :

Pubmed ID

31791386

DOI: Digital Object Identifier

PMC6889334

Related Literature

Article Analysis
・Effects of upadacitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.